Anecortave Acetate | CAS#7753-60-8 | Angiostatic Steroid

MedKoo Cat#: 524234 | Name: Anecortave Acetate

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Anecortave Acetate is an angiostatic steroid used for proteomics research. Anecortave acetate possesses a mechanism of action that decreases CNV growth irrespective of the inciting angiogenic stimulus, has a dosing-interval that allows its use as prophylactic therapy, and is safe.

Chemical Structure

Anecortave Acetate

CAS#7753-60-8 (acetate)

Theoretical Analysis

MedKoo Cat#: 524234

Name: Anecortave Acetate

CAS#: 7753-60-8 (acetate)

Chemical Formula: C23H30O5

Exact Mass: 386.2093

Molecular Weight: 386.48

Elemental Analysis: C, 71.48; H, 7.82; O, 20.70

Price and Availability

Size	Price	Availability
25mg	USD 90.00	Ready to ship
100mg	USD 150.00	Ready to ship
200mg	USD 250.00	Ready to ship
500mg	USD 550.00	Ready to ship
1g	USD 950.00	Ready to ship
5g	USD 3,650.00	Ready to ship

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

7753-60-8 (acetate) 10184-70-0

Synonym

Anecortave Acetate ; Anecortave; Al 3789; NSC 15475; NSC 24345; Retaane; Hydrocortisone Acetate EP Impurity E;

IUPAC/Chemical Name

17,21-Dihydroxypregna-4,9(11)-diene-3,20-dione 21-acetate

InChi Key

YUWPMEXLKGOSBF-GACAOOTBSA-N

InChi Code

InChI=1S/C23H30O5/c1-14(24)28-13-20(26)23(27)11-8-19-17-5-4-15-12-16(25)6-9-21(15,2)18(17)7-10-22(19,23)3/h7,12,17,19,27H,4-6,8-11,13H2,1-3H3/t17-,19+,21+,22+,23+/m1/s1

SMILES Code

C1=2[C@@]3(C(=CC(CC3)=O)CC[C@H]1[C@@H]1CC[C@@]([C@@]1(C)CC2)(C(COC(=O)C)=O)O)C

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO, not in water

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Certificate of Analysis

View CoA: current batch, Lot#A21T11K24

View CoA: current batch, Lot#T8R04C24

QC Data

View QC data: current batch, Lot#A21T11K24

Safety Data Sheet (SDS)

View Safety Data Sheet (SDS)

Instruction

View handling instruction

Biological target:

Anecortave acetate is an angiostatic agent.

In vitro activity:

TBD

In vivo activity:

The tumor control efficacy of the antiangiogenic agent anecortave acetate was evaluated in retinal tumor reduction using the LH(BETA)T(AG) mouse model of retinoblastoma. A significant (P = 0.012, quadratic dose–response) reduction in tumor size was seen at the lower doses (150–600 μg) of anecortave acetate tested (Fig. 1) . Whereas the highest dose (1200 μg) did not significantly reduce tumor size. Variability in tumor size was not significantly related to anecortave acetate dose (P = 0.12, Levine test). The dose–response curve followed a U-shaped, biphasic trend. Reference: Invest Ophthalmol Vis Sci. 2006 Apr;47(4):1264-8. https://iovs.arvojournals.org/article.aspx?articleid=2202975

	Solvent	mg/mL	mM
Solubility
	Soluble in DMSO, not in water	0.0	100.00

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 386.48 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Jockovich ME, Murray TG, Escalona-Benz E, Hernandez E, Feuer W. Anecortave acetate as single and adjuvant therapy in the treatment of retinal tumors of LH(BETA)T(AG) mice. Invest Ophthalmol Vis Sci. 2006 Apr;47(4):1264-8. doi: 10.1167/iovs.05-1194. PMID: 16565356.

In vitro protocol:

TBD

In vivo protocol:

1: Shepard AR, Conrow RE, Pang IH, Jacobson N, Rezwan M, Rutschmann K, Auerbach D, Sriramaratnam R, Cornish VW. Identification of PDE6D as a molecular target of anecortave acetate via a methotrexate-anchored yeast three-hybrid screen. ACS Chem Biol. 2013 Mar 15;8(3):549-58. doi: 10.1021/cb300296m. Epub 2013 Jan 9. PubMed PMID: 23301619. 2: Stalmans I, Callanan DG, Dirks MS, Moster MR, Robin AL, Van Calster J, Scheib SA, Dickerson JE Jr, Landry TA, Bergamini MV. Treatment of steroid-induced elevated intraocular pressure with anecortave acetate: a randomized clinical trial. J Ocul Pharmacol Ther. 2012 Dec;28(6):559-65. doi: 10.1089/jop.2012.0063. Epub 2012 Aug 3. PubMed PMID: 22860637; PubMed Central PMCID: PMC3505827. 3: Missel P, Chastain J, Mitra A, Kompella U, Kansara V, Duvvuri S, Amrite A, Cheruvu N. In vitro transport and partitioning of AL-4940, active metabolite of angiostatic agent anecortave acetate, in ocular tissues of the posterior segment. J Ocul Pharmacol Ther. 2010 Apr;26(2):137-46. doi: 10.1089/jop.2009.0132. PubMed PMID: 20415622; PubMed Central PMCID: PMC3158576. 4: Bajenaru ML, Piña Y, Murray TG, Cebulla CM, Feuer W, Jockovich ME, Marin Castaño ME. Gelatinase expression in retinoblastoma: modulation of LH(BETA)T(AG) retinal tumor development by anecortave acetate. Invest Ophthalmol Vis Sci. 2010 Jun;51(6):2860-4. doi: 10.1167/iovs.09-4500. Epub 2010 Jan 27. PubMed PMID: 20107171; PubMed Central PMCID: PMC2891454. 5: Prata TS, Tavares IM, Mello PA, Tamura C, Lima VC, Belfort R. Hypotensive effect of juxtascleral administration of anecortave acetate in different types of glaucoma. J Glaucoma. 2010 Sep;19(7):488-92. doi: 10.1097/IJG.0b013e3181c4b0e8. PubMed PMID: 20051887. 6: Robin AL, Suan EP, Sjaarda RN, Callanan DG, Defaller J; Alcon Anecortave Acetate for IOP Research Team. Reduction of intraocular pressure with anecortave acetate in eyes with ocular steroid injection-related glaucoma. Arch Ophthalmol. 2009 Feb;127(2):173-8. doi: 10.1001/archophthalmol.2008.595. PubMed PMID: 19204235. 7: Li X, Wang YS. [Present status of studies on the treatment of choroidal neovascularization by Anecortave acetate]. Zhonghua Yan Ke Za Zhi. 2008 Jun;44(6):571-4. Review. Chinese. PubMed PMID: 19035252. 8: El Filali M, Homminga I, Maat W, van der Velden PA, Jager MJ. Triamcinolone acetonide and anecortave acetate do not stimulate uveal melanoma cell growth. Mol Vis. 2008 Sep 24;14:1752-9. PubMed PMID: 18836566; PubMed Central PMCID: PMC2556975. 9: Robin AL, Clark AF, Covert DW, Krueger S, Bergamini MV, Landry TA, Dickerson JE Jr, Scheib SA, Realini T, Defaller JM, Cagle GD. Anterior juxtascleral delivery of anecortave acetate in eyes with primary open-angle glaucoma: a pilot investigation. Am J Ophthalmol. 2009 Jan;147(1):45-50.e2. doi: 10.1016/j.ajo.2008.07.039. Epub 2008 Sep 13. PubMed PMID: 18789793. 10: Aggermann T, Haas P, Binder S. Anecortave acetate for fibrotic lesions with presence of residual peripheral activity in age-related macular degeneration. Ann Ophthalmol (Skokie). 2008 Spring;40(1):28-30. PubMed PMID: 18556978. 11: Augustin A. Anecortave acetate in the treatment of age-related macular degeneration. Clin Interv Aging. 2006;1(3):237-46. Review. PubMed PMID: 18046876; PubMed Central PMCID: PMC2695182. 12: Hayek S, Scherrer M, Barthelmes D, Fleischhauer JC, Kurz-Levin MM, Menghini M, Helbig H, Sutter FK. First clinical experience with anecortave acetate (Retaane). Klin Monbl Augenheilkd. 2007 Apr;224(4):279-81. PubMed PMID: 17458792. 13: Jockovich ME, Murray TG, Clifford PD, Moshfeghi AA. Posterior juxtascleral injection of anecortave acetate: magnetic resonance and echographic imaging and localization in rabbit eyes. Retina. 2007 Feb;27(2):247-52. PubMed PMID: 17290209. 14: Slakter JS, Carvalho C, Coleman H. The Digital Angiography Reading Center (DARC) role in the anecortave acetate clinical trials. Surv Ophthalmol. 2007 Jan;52 Suppl 1:S91-8. Review. PubMed PMID: 17240261. 15: Russell SR, Hudson HL, Jerdan JA; Anecortave Acetate Clinical Study Group. Anecortave acetate for the treatment of exudative age-related macular degeneration--a review of clinical outcomes. Surv Ophthalmol. 2007 Jan;52 Suppl 1:S79-90. Review. PubMed PMID: 17240260. 16: Regillo CD, D'Amico DJ, Mieler WF, Schneebaum C, Beasley CH, Sullins GT. Clinical safety profile of posterior juxtascleral depot administration of anecortave acetate 15 mg suspension as primary therapy or adjunctive therapy with photodynamic therapy for treatment of wet age-related macular degeneration. Surv Ophthalmol. 2007 Jan;52 Suppl 1:S70-8. Review. PubMed PMID: 17240259. 17: Kaiser PK, Goldberg MF, Davis AA; Anecortave Acetate Clinical Study Group. Posterior juxtascleral depot administration of anecortave acetate. Surv Ophthalmol. 2007 Jan;52 Suppl 1:S62-9. Review. PubMed PMID: 17240258. 18: Dahlin DC, Rahimy MH. Pharmacokinetics and metabolism of anecortave acetate in animals and humans. Surv Ophthalmol. 2007 Jan;52 Suppl 1:S49-61. Review. PubMed PMID: 17240257. 19: Clark AF. Preclinical efficacy of anecortave acetate. Surv Ophthalmol. 2007 Jan;52 Suppl 1:S41-8. Review. PubMed PMID: 17240256. 20: Heaton J, Kastner P, Hackett R. Preclinical safety of anecortave acetate. Surv Ophthalmol. 2007 Jan;52 Suppl 1:S35-40. Review. PubMed PMID: 17240255.